Perspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold.
Affiliation
Stockport Health Authority, Stockport SK7 5BY. R.Foy@ed.ac.ukIssue Date
1999-02-13
Metadata
Show full item recordCitation
Perspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold. 1999, 318 (7181):456-9 BMJJournal
BMJPubMed ID
9974468Type
ArticleLanguage
enISSN
0959-8138Collections
Related articles
- Managing oncology drug costs in a constrained environment.
- Authors: Clark P
- Issue date: 2019 Feb
- Understanding the value of cancer drugs-the devil is in the detail.
- Authors: Goldstein DA
- Issue date: 2016 Aug 1
- A question of health. The lottery of cancer care.
- Issue date: 1997 Dec 18
- Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
- Authors: Low E, Myeloma UK
- Issue date: 2007 Jun 20
- Improving outpatient oncology practice: several steps into a long journey.
- Authors: Conti RM, Bach PB
- Issue date: 2014 Nov